FDA Panel Backs BPC-157 Pharmacy Dispensing in 8-6 Vote Despite Safety Concerns
Updated
Updated · The New York Times · Jul 23
FDA Panel Backs BPC-157 Pharmacy Dispensing in 8-6 Vote Despite Safety Concerns
3 articles · Updated · The New York Times · Jul 23
Summary
An FDA advisory committee voted 8-6 to add BPC-157 to the list of products specialized compounding pharmacies can dispense, marking an early win for broader access to a peptide the agency barred 3 years ago.
Six peptide sellers on the panel joined a compounding pharmacist and a pharmacy business executive to support the move, even as FDA scientists said the drug's risks and benefits remain poorly understood.
The hearing covers 7 peptide injections now sold online as “research grade” products and promoted for uses ranging from tendon repair to brain health despite restrictions on widespread use.
The panel's makeup has drawn scrutiny because FDA advisory committees are meant to be neutral, and the dispute could put agency scientists on a collision course with Health Secretary Robert F. Kennedy Jr.'s wellness-friendly agenda.